Myelodysplastic Syndromes: all 2,165 studies

Page 9 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & DisordersCompletedNCT00547196Not applicableResults posted
• Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological MalignanciesActive, not recruitingNCT00544466Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic SyndromeTerminatedNCT00542828Phase 2Results posted
• Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid CancerTerminatedNCT00540995Phase 1/2Results posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic CancerCompletedNCT00534430Phase 2Results posted
• Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicableResults posted
• A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)CompletedNCT00531232Phase 2Results posted
• Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell TransplantCompletedNCT00526292Phase 2Results posted
• Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDSCompletedNCT00520468Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerCompletedNCT00516503Phase 3Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Sorafenib in Myelodysplastic SyndromeTerminatedNCT00510289Phase 2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)TerminatedNCT00506948Phase 2Results posted
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00503880Phase 1/2Results posted
• Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersCompletedNCT00488592Phase 2Results posted
• Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)TerminatedNCT00486720Phase 2Results posted
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT00480987Phase 1/2Results posted
• Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)CompletedNCT00479232Phase 1Results posted
• Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00475150Phase 2Results posted
• Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic SyndromeCompletedNCT00475020Phase 2Results posted
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)CompletedNCT00472290Not applicableResults posted
• IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00469144Phase 3Results posted
• Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompletedNCT00469014Phase 2Results posted
• Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
• Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDSTerminatedNCT00467610Phase 2Results posted
• A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 StatusCompletedNCT00462761Phase 1Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi AnemiaCompletedNCT00453388Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaCompletedNCT00451048Phase 2Results posted
• Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesTerminatedNCT00450983Phase 2Results posted
• Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other DiseasesCompletedNCT00450450Phase 3Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00445744Not applicableResults posted
• PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDSCompletedNCT00439673Phase 2Results posted
• Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyCompletedNCT00433745Phase 2Results posted
• Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00425477Phase 2Results posted
• Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseCompletedNCT00423514Phase 1/2Results posted
• 2 Arm Study of Clofarabine IV in MDS PatientsCompletedNCT00422032Phase 2Results posted
• Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsCompletedNCT00418951Phase 2Results posted
• A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidCompletedNCT00418665Phase 2Results posted
• Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT00414310Phase 2Results posted
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)CompletedNCT00412360Phase 3Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaCompletedNCT00398138Phase 1Results posted
• Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00398047Phase 2Results posted
• Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
• DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00397579Phase 1/2Results posted
• Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other DiseaseTerminatedNCT00392782Phase 2Results posted
• A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic SyndromesCompletedNCT00384956Phase 2Results posted
• Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsCompletedNCT00382590Phase 2Results posted
• Decitabine and Tretinoin in Treating Patients With Myelodysplastic SyndromesCompletedNCT00382200Phase 1/2Results posted
• Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic SyndromesTerminatedNCT00379912Phase 2Results posted
• Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsCompletedNCT00378534Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00369317Phase 3Results posted
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
• Vaccine Therapy in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00361296Early Phase 1Results posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00360672Phase 2Results posted
• Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaCompletedNCT00357565Phase 2Results posted
• Belinostat in Treating Patients With Myelodysplastic SyndromesCompletedNCT00357162Phase 2Results posted
• Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.TerminatedNCT00354172Phase 2Results posted
• Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00352001Phase 1/2Results posted
• An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous LeukemiaTerminatedNCT00346632Phase 1Results posted
• Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDSCompletedNCT00334074Phase 2Results posted
• Phase II 5-Azacytidine Plus VPA Plus ATRACompletedNCT00326170Phase 2Results posted
• Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaCompletedNCT00322101Phase 3Results posted
• Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell TransplantCompletedNCT00321932Phase 2Results posted
• Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsCompletedNCT00321711Phase 2Results posted
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
• Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantCompletedNCT00309907Phase 2Results posted
• Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
• Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood TransplantCompletedNCT00305682Phase 2Results posted
• Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
• Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00303472Phase 2Results posted
• Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 2Results posted
• Oral Clofarabine Study in Patients With Myelodysplastic SyndromeCompletedNCT00299156Phase 2Results posted
• Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00274781Phase 2Results posted
• Bortezomib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00262873Phase 2Results posted
• A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic SyndromesCompletedNCT00260065Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00253513Phase 1/2Results posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic SyndromeCompletedNCT00217594Phase 2Results posted
• Haploid Allogeneic Transplant Using the CliniMACS SystemTerminatedNCT00185679Phase 2Results posted
• Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] AbnormalityCompletedNCT00179621Phase 3Results posted
• Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
• Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted

← Myelodysplastic Syndromes overview